SCIENTIFIC CODE OF CONDUCT

1. OVERVIEW

1.1. This Scientific Code of Conduct describes fundamental principles of behavior and standards of conduct for clinical research activities performed or supported by Dynavax Technologies Corporation.

1.2. Dynavax strives to maintain high ethical principles, as well as high scientific and clinical standards, in all of its research activities. All Dynavax-sponsored trials are designed and conducted to standards that meet or exceed all applicable national and state/provincial laws, as well as widely accepted international research standards. Dynavax is committed to serving patients, and its clinical research activities are carefully designed to achieve this goal.

2. INTEGRITY OF RESEARCH

2.1. Research integrity is of fundamental importance to Dynavax. All research is conducted with the intent of enhancing clinical and/or scientific knowledge for the ultimate goal of benefiting patients. Research is performed in accordance with applicable laws, regulations and requirements, including, but not limited to, the Federal Food, Drug, and Cosmetic Act, and laws and regulations pertaining to federal health care programs.

3. SELECTION OF INVESTIGATORS AND/OR SITES

3.1. Dynavax selects clinical investigators based on such individuals’ qualifications, training, prior research, clinical expertise in relevant fields, potential to recruit eligible research participants and ability to conduct research in a manner that is consistent with the principles contained in this Scientific Code of Conduct.

3.2. No investigator or site is selected to perform research if one of the reasons for that selection is to induce the clinical investigator or site to (a) begin, continue or increase the purchase, usage, or ordering of Dynavax products, (b) arrange for or recommend the purchase, usage, or ordering of Dynavax products, (c) reward the investigator or site for prior purchases, usage or orders of Dynavax products, and/or (d) reward the investigator or site for previously arranging for, promoting, advocating, or recommending the purchase, use, or order of Dynavax products.

3.3. Dynavax respects the independence of investigators and others involved in research so that they can act in accordance with their ethical and legal duties to protect the best interests of research participants, while rigorously implementing approved Research protocols.

3.4. Dynavax does not engage any clinical investigators or sites that have been debarred, disqualified or restricted from participating in research by a governmental authority.

4. HUMAN SUBJECTS AND HUMAN SUBJECT RECRUITMENT

4.1. The rights, dignity, safety and well-being of research participants are of critical importance to Dynavax. Research involving human subjects must comply with all applicable laws and regulations relating to the protection of human subjects.
4.2. Dynavax ensures that informed consent outlines the known benefits and risks of participating in a clinical trial. Dynavax takes additional steps to ensure appropriate informed consent for vulnerable human research participants, such as minors.

4.3. The number of human subjects or human biological specimens in research must be no larger than is necessary to accomplish the purposes of the research. Collection and utilization of human biological material must be consistent with the consent obtained.

5. COMPENSATION

5.1. Payments from Dynavax to any clinical investigators or institutions conducting research are consistent with fair market value for research-related services rendered by those researchers and institutions.

6. PRIVACY

6.1. Dynavax is committed to respecting and protecting human research participant privacy and complying with all applicable privacy laws. Dynavax will ensure that its collection of participant information is consistent with all applicable privacy laws, and with guidelines for good clinical practice, when appropriate.

7. STANDARD OF CARE

7.1. Dynavax ensures that research is designed and monitored to protect the rights and well-being of research participants. The standard of care provided to control groups is, at a minimum, equivalent to well-established and commonly employed local treatment.

8. QUALITY OF CLINICAL DATA

8.1. Dynavax uses established data standards to ensure that data are reliable and have been processed and reported correctly.

9. SAFETY MONITORING

9.1. Dynavax is committed to ensuring that research participants are appropriately monitored throughout clinical trials, including long-term follow-up as may be required by drug regulatory authorities. Adverse event information regarding Dynavax products is collected, processed, reported, analyzed and communicated in a timely manner. Dynavax continuously monitors the safety of its products by ensuring clinical investigators appropriately report adverse event information and update research participants and others, as appropriate, of any new significant risks associated with the use of the investigational drug that arise during the course of the clinical trial.

10. TRANSPARENCY

10.1. Dynavax makes research results available to external persons in compliance with all applicable laws and regulations and with Dynavax policies on clinical trial transparency.